NEW YORK (GenomeWeb News) – NextBio and Genophen today said they are partnering to drive adoption of genomics for disease prevention and wellness.

They said the deal allows Genophen to interpret genomic sequencing data from patients through the use of NextBio's clinical platform and to combine this information with data about a patient's environmental, behavioral, and clinical factors "to create a uniquely tailored disease prevention and wellness plan for its individual member."

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.